Novo Nordisk Hopes Victoza's EU Clearance Bodes Well For U.S.
This article was originally published in The Pink Sheet Daily
Executive Summary
GLP-1 inhibitor approved in Europe without restrictions on use, but Novo Nordisk will conduct a five-year cardiovascular outcomes trial.
You may also be interested in...
Novo Disappoints With No Liraglutide News, But Growth Is Strong
Novo delivered strong first-half results, but provided little further clarity on liraglutide's progress at FDA.
Novo Disappoints With No Liraglutide News, But Growth Is Strong
Novo delivered strong first-half results, but provided little further clarity on liraglutide's progress at FDA.
Victoza Outperforms Byetta In Head-To-Head Trial
Head-to-head trial results presented at the American Diabetes Association meeting are positive, but safety questions aren't likely to go away.